Chimeric Therapeutics (ASX:CHM) secures cell therapy patent protection in the US

Be the First to Comment Read
Sponsored

Chimeric Therapeutics (ASX:CHM) secures cell therapy patent protection in the US

 Chimeric Therapeutics (ASX:CHM) secures cell therapy patent protection in the US
Image source: © Konevaelvira | Megapixl.com

Highlights

  • Chimeric Therapeutics has been granted patent protection for CLTX CAR therapies from the US Patent and Trademark Office.
  • For biopharmaceutical products, the United States is the single largest market globally.
  • The US patent grant will leg up the intellectual property portfolio that supports the Company’s CLTX CAR pipeline assets.
  • In September last year, the Company secured patent grant in Europe.

The ASX leader in cell therapy, Chimeric Therapeutics Limited (ASX:CHM) has been making unwavering efforts to pull in its commitment of making cell therapy accessible for more cancer patients.

Steering forward on its journey, the Company has secured a patent from the United States Patent and Trademark Office for chimeric antigen receptor (CAR) technology related applications. The US grant will leg up the intellectual property portfolio that supports further development of the Company’s CLTX CAR pipeline assets.

MUST READ: Chimeric Therapeutics partners with Oncobay Clinical to advance clinical trials

Focal points of the new patent

The patent entitled “Chimeric antigen receptors containing a chlorotoxin domain” is for the use of chlorotoxin (CLTX) chimeric antigen receptor (CAR) technology in Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinical-stage CAR NK asset CHM 1301.

Key details of the granted patent 

Image Source: © Designer491 | Megapixl.com

Developed by a team of experts at California’s City of Hope Medical Centre, CHM 1101 (CLTX CAR T) is a new CAR T therapy being developed to treat patients with solid tumours. It is presently being studied for recurrent/progressive glioblastoma in a phase 1 clinical trial. The second CLTX CAR T phase 1 clinical trial will commence later in the year in other solid tumours.

The new patent has the patent number US 11,230,577 B2. The clinical-stage cell therapy company holds the exclusive global license for the development and commercialisation of US 11,230,577 B2 and related patent applications filed in other territories across the world.

Also read: CHM ticks off a crucial milestone; secures IND clearance for CHM 1101

Remarks by Chimeric’s CEO and Managing Director Jennifer Chow

“We are delighted to have patent protection granted for CLTX CAR therapies in the United States, the single largest global market for biopharmaceutical products. The granting of this key US patent continues the momentum for the intellectual property portfolio underpinning our CLTX CAR pipeline assets, following the recent patent grant in Europe in September.”

Stock information: CHM shares were trading at AU$0.220 in the early hours of 28 January 2022, with a market capitalisation of AU$73.83 million.

Do read: CHM adds three more experts to Cellular Immunotherapy Scientific Advisory Board

Disclaimer

Speak your Mind

Featured Articles

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK